Last reviewed · How we verify
NCT07125092: LIP'EX
A Study to Evaluate the Clinical Benefit and Safety of Medical Compression Garments in the Management of Patients With Lipedema
NA trial testing compression group in Lipoedema in 30 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | Thuasne |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- compression group
Conditions studied
- Lipoedema — all drugs for Lipoedema →
Sponsor
Thuasne
Who can join
18 and older, any sex, with Lipoedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lipedema (LI) is a chronic condition, painful disease characterized by a disproportionate increase in adipose tissue and pain in women's legs and sometimes arms. Its prevalence is largely unknown, but lipedema is estimated to affect 0.06% to 11% of the female population. Even though this pathology is increasingly studied and working groups are collaborating to harmonize criteria, a crucial underlying problem of lipedema is the variability in identifying lipedema. Lipedema patients often suffer from obesity, physical disability and psychological impairments, and the effects on quality of life are significant. Almost all women with lipedema are dissatisfied with the disproportionality of their body and the stigma associated with it. In addition to weight gain, pain is one of the major symptoms of this pathology, but also limb heaviness, weakness, or difficulties with walking. Patients also tend to develop easy bruising, although these symptoms are not always present. Treatment of lipedema is aimed at relieving pain, maintaining/improving mobility, reducing volume of the limbs, and improving quality of life. It is important to note that compression therapy is one of the cornerstones of this treatment because of its anti-inflammatory effect on adipose tissue
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07125092
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Thuasne trials
Trials by the same sponsor.
- NCT06264817 — Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. · NA · recruiting
- NCT05905809 — Efficacy of UniRelieverTM Offloading Brace in the Management of Knee Osteoarthritis · NA · completed
- NCT05716165 — Effect of Proprioceptive Knee Braces on the Performance and Endurance of Recreational Soccer Players Aged 60-80 Years · NA · completed
- NCT05435040 — Evaluation of Proprioceptive Abilities While Wearing an Elastic Orthosis in Patients With Proprioceptive Knee Deficits · NA · completed
- NCT05600543 — Evaluation of the Effect of Lumbar Belt on Spinal Mobility in Subjects With and Without Low Back Pain · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07125092 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thuasne
- Last refreshed: 15 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07125092.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing